Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 1/20 | 0.53 |
| ▸ | CASP3 | P42574 | 3/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | CA9 | Q16790 | 2/20 | 0.49 |
| ▸ | CA4 | P22748 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.47 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.47 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29831635 | 1.00 | GLS (0.53) | GLSCASP3CA1CA2CA9 | |
| SCHEMBL2286757 | 0.89 | TDP1 (0.51) | GLSRAB9ASMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL26751756 | 0.88 | CASP3 (0.42) | GLSCASP3CA1CA2CA9 | |
| SCHEMBL4190379 | 0.87 | TDP1 (0.54) | RAB9ASMN1; SMN2TDP1L3MBTL1MAPT | |
| SCHEMBL25123877 | 0.86 | TDP1 (0.57) | TDP1L3MBTL1 | |
| SCHEMBL19585886 | 0.86 | TDP1 (0.57) | TDP1L3MBTL1 | |
| SCHEMBL29384939 | 0.86 | TDP1 (0.57) | TDP1L3MBTL1 | |
| SCHEMBL4183460 | 0.86 | TDP1 (0.57) | TDP1L3MBTL1 | |
| SCHEMBL29991217 | 0.86 | TDP1 (0.57) | TDP1L3MBTL1 | |
| SCHEMBL11502328 | 0.86 | TDP1 (0.57) | TDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 500 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0355098-A1 | NOVEL SULFONAMIDES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE NEW SULFONAMIDES | HUHTAMÄKI OY (FI) | 1990-02-28 | — | — | EP | claimed |
| WO-1988007991-A1 | NOVEL SULFONAMIDES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE NEW SULFONAMIDES | Huhtamäki Oy (FI) | 1988-10-20 | — | — | WO | claimed |
| US-12466821-B2 | Antiviral pyridopyrazinedione compounds | NOVARTIS AG (CH) | 2025-11-11 | — | — | US | disclosed |
| US-12466809-B2 | CDK2/5 degraders and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| EP-3947368-B1 | BIFUNCTIONAL COMPOUNDS COMPRISING A CDK2/5 LIGAND, A LINKER AND A E3 UBIQUITIN LIGASE BINDING DEGRON FOR THE TREATMENT OF CANCER | DANA FARBER CANCER INST INC (US) | 2025-09-03 | — | — | EP | disclosed |
| US-12187742-B2 | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | XRAD THERAPEUTICS, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| CN-118440092-A | Thienopyrimidine compound and application thereof | 中国科学院基础医学与肿瘤研究所(筹) | 2024-08-06 | — | — | CN | disclosed |
| WO-2024147972-A2 | DNA POLYMERASE THETA INHIBITORS CONTAINING NON-SATURATED 5-MEMBERED HETEROCYCLIC RINGS AND USE THEREOF | THOMAS JEFFERSON UNIVERSITY (US) | 2024-07-11 | — | — | WO | disclosed |
| CN-118307515-A | Antibacterial compounds | 英菲克斯治疗有限公司 | 2024-07-09 | — | — | CN | disclosed |
| CN-112469720-B | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | 艾科思莱德制药公司 | 2024-03-29 | — | — | CN | disclosed |
| EP-4327877-A2 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRad Therapeutics, Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| WO-1981003492-A1 | CHEMICAL COMPOUNDS,THEIR PRODUCTION,AND THEIR USE IN DRUGS | MEDICA PHARMA CO LTD (FI) | 1981-12-10 | — | — | WO | disclosed |
| US-4159373-A | 7-Acyl-3-(sulfonic acid and sulfamoyl substituted tetrazolyl thiomethyl) cephalosporins | SMITHKLINE CORPORATION (US) | 1979-06-26 | — | — | US | disclosed |
| US-4140694-A | BACTERICIDES | SMITHKLINE CORPORATION (US) | 1979-02-20 | — | — | US | disclosed |
| US-4139701-A | BACTERICIDES | SMITHKLINE CORPORATION (US) | 1979-02-13 | — | — | US | disclosed |
| US-4118490-A | ANTIBACTERIAL ACTIVITY | SMITHKLINE CORPORATION (US) | 1978-10-03 | — | — | US | disclosed |
| US-4093723-A | ANTIBIOTICS | SMITHKLINE CORPORATION (US) | 1978-06-06 | — | — | US | disclosed |
| US-4066762-A | ANTIBACTERIAL | SMITHKLINE CORPORATION (US) | 1978-01-03 | — | — | US | disclosed |
| US-4063014-A | ANTIBIOTICS | ABBOTT LABORATORIES (US) | 1977-12-13 | — | — | US | disclosed |
| US-4048311-A | ANTIBACTERIAL | SMITHKLINE CORPORATION (US) | 1977-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12466809-B2 | CDK2/5 degraders and uses thereof | CDK2, CDK5, CDK5R1 | GLS 3081/4885CASP3 2126/4885CA1 3862/4885 |
| US-12466821-B2 | Antiviral pyridopyrazinedione compounds | ZC3HAV1, IL5, TYMP | GLS 3180/4885CASP3 2447/4885CA1 4711/4885 |
| US-12187742-B2 | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | ATM, CHEK2, CHEK1 | GLS 1754/4885CASP3 1885/4885CA1 4810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.